tbuckley/cabot-search huggingface dataset:
DISCUSSION ON ADDRESS OF THE CHAIRMAN, DR. WILLIAM E. QUINE, OF CHICAGO.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Metal Interactions in Carcinogenesis: Enhancement, Inhibition
Authors: Gunnar F. Nordberg, Ole Andersen
Journal: Environmental Health Perspectives (1981)

Metals constitute a fundamentally important part of the total human environment. Since human exposure often involves complex mixtures of metal compounds and, possibly, organic compounds which may be carcinogenic per se, interactions between these compounds may add significantly to human cancer risk. Our present knowledge about these kinds of interactions is very limited. The best investigated area is benzo(a)pyrene (BP)-metal oxide particle interactions in respiratory carcinogenesis in the hamster. Metal oxide particles were also shown to modify the carcinogenic effect of nitrosamines. Several reports describe experiments in which selenium compounds exerted a generally anticarcinogenic and antimutagenic activity. Inorganic arsenic compounds, which are accepted to be carcinogenic in man, have so far been negative in animal experiments except for one recent suggested report. Several authors have, however, suggested that these compounds may act as cocarcinogens due to their inhibition of DNA repair, although animal experiments to demonstrate a cocarcinogenic effect of arsenic compounds have been negative so far, except for one preliminary report. The concentration of zinc in the diet seemed to influence both transplanted tumor growth and the carcinogenicity of several organic compounds, and the possibility of a correlation between dietary zinc and certain cancer forms in man has been suggested. Protection against development of Leydigiomas usually induced by cadmium injection was afforded by simultaneous injection of zinc salts. Nickel carcinogenesis has been reported to be antagonized by manganese, and synergism between Ni and organic carcinogens, e.g. BP, has been demonstrated. There is no firm evidence that lead may be a cocarcinogen, although some limited experimental evidence is available. Oxidizing agents have been demonstrated to increase, and reducing agents to antagonize, the mutagenic effect of chromium compounds in vitro. The content of carcinogenic and other metals in asbestos has been suggested to modify the carcinogenic properties of asbestos. Since much of the information available at present is suggestive, further research on these interactions as well as other possible interactions in metal carcinogenesis is needed. Studies should be made both in well defined in vitro systems and in relevant animal models.
Itraconazole-didanosine excipient interaction
Authors: F. Moreno
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Achalasia and carcinoma of the esophagus
Authors: A. R. Wychulis
Journal: JAMA (1971)

A total of 1,318 patients first treated for esophageal achalasia from 1935 to 1967 at the Mayo Clinic were observed an average of 13 years per patient. Carcinoma developed in seven of these patients, an incidence of 41 cases per year per 100,000. An additional six patients with achalasia and carcinoma of the esophagus had their initial treatment for achalasia either before 1935 or elsewhere than the Mayo Clinic. Achalasia had been present an average of 28 years prior to the diagnosis of carcinoma. The appearance of symptoms suggesting the possibility of esophageal malignancy occurred from two weeks to four years prior to diagnosis. Malignant tumors arose at all levels of the esophagus, and the majority were squamous cell carcinomas. Although surgical exploration was carried out in seven instances, there was only one survivor without evidence of tumor.
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial
Authors: Andrzej J Jakubowiak, Donna E. Reece, Craig C. Hofmeister, Sagar Lonial, Todd M Zimmerman, Erica L. Campagnaro, Robert L. Schlossman, Jacob P. Laubach, Noopur Raje, Tara B. Anderson, Kent A. Griffith, Melissa A. Hill, Colleen K. Harvey, Sandra Wear, Jennifer Barrickman, Craig L. Tendler, Dixie-Lee Esseltine, Susan L. Kelley, Mark S. Kaminski, Kenneth C. Anderson, Paul G. Richardson
Journal: Blood (2010)
Abstract 4431: Cytotoxic effects of the Jamaican yam tuber in hormone-sensitive cancers and its potential use in green nanotechnology formulation
Authors: Sasha-gay A. Wright
Journal: Cancer Research (2019)

Abstract Historically, plant materials have been widely explored for their anti-proliferative effects against a variety of cancer cells, with many of them proving to be very effective. Additionally, their efficacy has been seen in the specific field of targeted cancer therapy. The use of plants for therapeutic purposes in place of or with traditional medicine is collectively referred to as complementary and alternative medicine (C.A.M). Several Jamaican Yam species have shown to be useful as C.A.M in the treatment of certain medical conditions such as diabetes, hypercholesterolemia and cancer. Hormone-sensitive cancers such as breast and prostate cancer are the most frequently diagnosed malignancy and when combined, is the leading cause of cancer related deaths among the Jamaican populace. These statistics unfortunately, are also reflected in the wider Caribbean region. Currently treatment involves: surgery, radiation and androgen deprivation therapy; however, there are some cases in which mutation causes further growth of the cancer cells regardless of treatment. As such, there still remains a dire need of a more effective and lasting therapy. The aim of this study was to assess the antiproliferative effects of yam material and to also deduce a possible mechanism of action in an effort to formulate a means of targeted therapy. The results showed that an alcoholic extract of the Jamaican yam tuber (Dioscorea spp.) demonstrated anti-proliferative effects in androgen insensitive prostate cancer cell lines (IC50 of 18 ppm, 95% C.I. 24-33ppm) and invasive breast cancer cell lines (IC 50 of 28 ppm, 95% C.I 36-54ppm). Western blot assays also indicated that cell death was possibly induced through the cell cycle regulatory protein, cyclin D. The antiproliferative effects and purported mechanism of action of the yam extract against some hormone-sensitive cancer cells makes it an ideal alternative for the formulation of green nanotechnology for targeted therapy. Note: This abstract was not presented at the meeting. Citation Format: Sasha-gay A. Wright. Cytotoxic effects of the Jamaican yam tuber in hormone-sensitive cancers and its potential use in green nanotechnology formulation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4431.
Taste perception in cirrhosis: Its relationship to circulating micronutrients and food preferences
Authors: A Madden
Journal: Hepatology (1997)

Impairment of gustatory acuity may influence nutrient intake and hence nutritional status. The aim of this study was to evaluate gustatory acuity in patients with cirrhosis and its relationship to circulating concentrations of micronutrients, and food preferences. Gustatory evaluation was undertaken, using a rinsing technique, in 75 cirrhotic patients and 75 comparable healthy volunteers. Circulating concentrations of magnesium, zinc, vitamin A, and α- and β-carotene were measured, and food preferences were assessed by questionnaire. The cirrhotic patients showed impaired gustatory function with significantly higher (less sensitive) median thresholds for detection of salt, sweet, and sour and for recognition of bitter, salt, sweet, and sour, together with a higher overall median gustatory score (P < .0001). Mean circulating concentrations of magnesium, zinc, vitamin A, and α- and β-carotene were significantly lower in the patient population. Serum magnesium was significantly negatively associated with detection of salt (P = .02) and gustatory score (P = .02). Patients' subjective assessment of taste acuity did not correspond with objective measurements. Overall, no differences were observed in food preferences between the two groups, nor was any association found between food preferences and gustatory acuity. Patients with cirrhosis have impaired gustatory acuity that is associated with hypomagnesemia but apparently does not affect food selection.
NCCN NewsTimothy J. Eberlein, MD, Elected Chairman of the NCCN Board of Directors; New Officers ElectedNCCN Welcomes University of Wisconsin Carbone Cancer Center to Its Alliance of Leading Cancer CentersNCCN Holds Fifth Annual State Oncology Society Forum to Discuss Value in Cancer Care, Best PracticesNCCN 21st Annual Conference Convened Experts in Key Oncology Issues; New and Updated NCCN Guidelines Presented
Journal: Journal of the National Comprehensive Cancer Network (2016)
Two-Week Course in Cancer Chemotherapy, October 20–31, 1958
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Two-Week Course in Cancer Chemotherapy, October 20–31, 1958 Get access JNCI: Journal of the National Cancer Institute, Volume 21, Issue 2, August 1958, Page 427, https://doi.org/10.1093/jnci/21.2.427 Published: 01 August 1958
SANITARY AND INSANITARY PLUMBING.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>ERJ</i>Podcast August 2017: Fevipiprant in allergic asthma not controlled by low-dose inhaled corticosteroids
Journal: European Respiratory Journal (2017)

As part of the August issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Marc Humbert discusses the publication of the results of a trial of fevipiprant, an oral prostaglandin in DP2 receptor (CRTh2) antagonist, in allergic asthma that is not controlled by low-dose inhaled corticosteroids with Prof. Eric D. Bateman from the University of Cape Town, South Africa.
MYOSITIS OSSIFICANS
Authors: DEAN LEWIS
Journal: JAMA (1923)

Cases of circumscribed myositis ossificans have been reported with increasing frequency during the last few years. It is probable that the condition is more common than even the large number of reported cases would indicate, for when ossification is not extensive and not in such a position that the motion of a joint is limited or a definite disability occurs, a physician is not consulted. The circumscribed form of myositis ossificans is of special interest to the surgeon because of its association with dislocations and fractures; because of the difficulties sometimes encountered in making a differential diagnosis, and because of the relation of periosteal stripping and displacement to heterologous bone formation. Three forms of circumscribed myositis are recognized: The traumatic: (a) Occupational myositis ossifications due as a rule to repeated injuries. (b) Myositis ossificans due to repeated injuries not sustained in pursuit of an occupation. (c) Myositis ossificans due to
Blood pressure rebound following withdrawal of antihypertensive treatment
Authors: M. A. Weber
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum
Authors: Michael Kundi, Leonardo Trasande, Philip Landrigan, Clyde Schechter, Richard Bopp, Charles Griffiths, Al Mcgartland, Maggie Miller, Eric Konofal, Samuele Cortese, Joe Braun, Bruce Lanphear, Robert Kahn, Tanya Froehlich, Peggy Auinger
Journal: Environmental Health Perspectives (2007)

ADHD in those subjects with low ferritin levels.Given that lead exposure may contribute to ADHD and iron deficiency may exacerbate deleterious effects caused by lead, we recommend systematically seeking for iron deficiency in children with ADHD.We also think that controlled studies assessing the potential effectiveness of iron supplementation on ADHD symptoms should be encouraged.Such studies could aid the understanding of the complex pathophysiology underlying ADHD and provide effective therapeutic strategies for this disorder.
A phase II trial of gemcitabine and S-1 therapy in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP-03).
Authors: Akio Saiura, Hideki Ueno, Tomoo Kosuge, Yutaka Matsuyama, Hiroshi Ishii, Akimasa Nakao, Ryuichiro Doi, Masao Tanaka
Journal: Journal of Clinical Oncology (2012)

263 Background: Although anti-tumor effect of gemcitabine (G) and S-1 (S) therapy is high for advanced pancreatic cancer (PC) patients, safety and effectiveness of postoperative GS adjuvant therapy has not been fully examined. Methods: Eligibility criteria included macroscopically curative resection of invasive ductal PC and no prior chemotherapy. Patients were recruited in 19 institutes. The primary endpoint was overall survival (OS). The patients received G (800 mg/m 2 /week) intravenously over 30 min on day 1 and S (60 mg/m 2 /day) orally twice daily from days 1 to 7 every 14 days for 12 cycles. Results: Fifty-five patients were enrolled in this study. One patient was excluded from the analysis due to no malignant pathology. Remaining 54 patients were analyzed. Deaths were observed in 17 patients (31.5%). Median overall survival was not reached. Estimated 1-year and 2-year OS were 88.9% (95% CI, 76.9-94.8) and 72.1% (95%CI, 58.1-82.2), respectively. Recurrences were observed in 31 patients (57.4%). Estimated 1-year and 2-year disease-free survival were 57.4% (95% CI, 43.2-69.3) and 44.4% (95%CI, 30.9-57.0), respectively. G3 febrile neutropenia was observed in 1.9 % of the patients, whereas the most common adverse reactions were neutropenia (G3/4: 59.2%, G4: 25.9%). There were no G4 adverse events except neutropenia and hyperkalemia (1.9%). G3 adverse events included anemia (3.7%), alanine aminotransferase elevation (3.6%), fatigue (1.9%), nausea (1.9%), vomiting (1.9%) and infection without neutropenia (1.9%). The protocol treatments could not finish in 6 patients due to adverse reactions. Conclusions: Our phase II results suggest that the postoperative GS therapy is a promising regimen that merits further investigation. Phase III trial of postoperative G versus GS therapy is now going on (JSAP-04).
Manuscripts Approved for JNCI, April 1 to May 1, 1970
Journal: JNCI Journal of the National Cancer Institute (1970)

Manuscripts Approved for JNCI, April 1 to May 1, 1970 Get access JNCI: Journal of the National Cancer Institute, Volume 44, Issue 6, June 1970, Page 1392, https://doi.org/10.1093/jnci/44.6.1392 Published: 01 June 1970
Personal Physicians
Authors: PAUL J. SANAZARO
Journal: Annals of Internal Medicine (1973)

Comments and Corrections1 July 1973Personal PhysiciansPAUL J. SANAZARO, M.D.PAUL J. SANAZARO, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-79-1-135_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: This is a belated and partial reply to the questions that you raised in your editorial in the March issue (pp. 448-449), "What Is the Practice of Personal Medicine?"Several years ago, with Dr. John Williamson, I conducted a study that addressed some of the questions that you raise (Physician performance and its effects on patients. A classification based on reports by internists, surgeons, pediatricians and obstetricians.Medical Care8:299-308, 1970). The intent of the study was to obtain as accurate as possible a documentation of the full range of physician performance and to determine the relationships... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 July 1973Volume 79, Issue 1Page: 135-136KeywordsSurgeons Issue Published: 1 July 1973 PDF DownloadLoading ...
Surveillance of drug therapy
Authors: J. K. Weston
Journal: JAMA (1969)

Early last year the state of the art of adverse drug reaction reporting was assessed inThe Journal,<sup>1</sup>found severely wanting, and suggestions voiced for its improvement. In this issue, the two communications by Jick, Slone, and associates from the Lemuel Shattuck Hospital, Boston, report two of the early fruits of a carefully conceived in-hospital drug surveillance program. This is a study of considerable depth and sophistication. It employs full-time paramedical personnel and insists on putting into the computer complete data on all drugs received by patients, as well as much potentially meaningful clinical data, all of which seems adequately and carefully monitored and validated under close nursing and medical supervision. The profile data covers many significant features in each patient, including genetic markers, such as the ABO, MNSs, and other blood groups, when available. By this means, a data bank has resulted which is continually expanding and which
Clinical activity of enzalutamide (Enza) pre- and post-docetaxel in men with metastatic castration-resistant prostate cancer (mCRPC).
Authors: Rosa Nadal, Zhe Zhang, Hitesh Raheja, Mario A. Eisenberger, Emmanuel S. Antonarakis
Journal: Journal of Clinical Oncology (2014)

e16001 Background: Enza is an AR signaling inhibitor that is FDA approved for mCRPC patients treated with docetaxel. Laboratory and clinical evidence of cross-resistance between taxanes and AR-targeted therapies makes optimal sequencing of docetaxel and Enza challenging. Here, we retrospectively evaluated the differential efficacy of Enza in the pre- (preD) and post-docetaxel (postD) settings. Methods: Men with mCRPC who received Enza preD or postD were identified from our institutional database. We investigated factors influencing Enza activity using univariate and multivariable Cox regression models, with particular attention to whether or not prior D was used. Outcome measures included PSA response rates, time to PSA progression (TTPP) and progression-free survival (PFS). Results: 90 men received Enza at our institution: 33 were preD and 57 were postD. PSA response rates were 41.9% and 25.5% in preD and postD patients, respectively. Median TTPP was 9.0 mo (95% CI: 3.5–NE) in the preD cohort and 2.5 mo (95% CI: 1.9–3.2) in the postD cohort (P=.0001). Median PFS was not reached in preD patients and was 3.2 mo (95% CI: 2.5–4.3) in postD patients (P=.0006). In univariate Cox regression analysis, lack of prior D treatment was associated with longer TTPP on enzalutamide (HR 0.29, 95%CI 0.16–0.53, P=.0001) and longer PFS (HR 0.33, 95%CI 0.17–0.64, P=.001). In multivariable analysis, prior use of D remained a poor prognostic factor with respect to TTPP (HR 0.39, 95%CI 0.17–0.87, P=.021) and PFS (HR 0.41, 95%CI 0.17–0.99, P=.047), after adjusting for several known clinical variables including Gleason sum, number of prior AR-directed therapies, baseline PSA, baseline alkaline phosphatase, and extent of disease. Conclusions: These data reveal numerically inferior PSA response rates and statistically inferior TTPP and PFS outcomes to Enza in men previously treated with D compared to D-naïve patients. The negative prognostic impact of prior D use on TTPP and PFS was maintained after adjusting for baseline prognostic factors. The lower activity of Enza observed postD might be due to taxane-induced AR signaling changes supporting the hypothesis of cross-resistance between Enza and docetaxel.